에이프릴(단백질)

TNFSF13
사용 가능한 구조
PDB	Ortholog 검색: PDBe RCSB
PDB ID 코드 목록
	4ZCH
식별자
에일리어스	TNFSF13, APRIL, CD256, TOL-2, TOL2, TRDL-1, ZTNF2, UNQ383/PRO715, TNLG7B, 종양괴사인자 슈퍼패밀리 멤버 13, TNF 슈퍼패밀리 멤버 13
외부 ID	OMIM : 604472 MGI : 1916833 HomoloGene : 56971 GenCard : TNFSF13
유전자 위치(인간)
크르.	17번 염색체(인간)
끝.	7,561,608 bp
유전자 위치(마우스)
크르.	11번 염색체(쥐)
끝.	69,576,610 bp
RNA발현패턴
	상단 표시 위치:
	단구; ; 십이지장; ; 담낭; ; 피; ; 오른쪽 폐; ; 좌폐 상엽; ; 신장; ; 직장; ; 침샘; ; 미산핵;
	추가 참조 표현식 데이터
	없음
유전자 존재론
분자 함수	신호수용체결합; 종양괴사인자수용체결합; 사이토카인 활성;
셀룰러 컴포넌트	세포; 막; 핵소체; 세포질; 세포외 엑소좀; 세포외 영역; 세포외 공간;
생물학적 과정	종양괴사인자결합신호경로; mRNA 안정성 조절; 세포군 증식의 양성 조절; 면역계 과정; 신호 변환; IgA 등형으로의 등형 전환의 양성 조절; 면역 반응; 신호수용체활성조절;
	출처:아미고 / QuickGO
맞춤법
	8741
	69583
	ENSG00000161955
	ENSMUSG000089669
	O75888
	Q9D777
NM_001198622; NM_001198623; NM_001198624; NM_003808; NM_172087;
	NM_172088
	NM_001159505; NM_023517
NP_00118551; NP_00118552; NP_00118553; NP_003799; NP_742084;
	NP_742085
	NP_001152977; NP_076006
	위키데이터
인간 보기/편집	마우스 표시/편집

종양괴사인자배위자 슈퍼패밀리 멤버13(TNFSF13)이라고도 불리는 증식유도배위자(APRIL)는 세포표면수용체 TACI에 ^[5]^[6]의해 인식되는 TNF 슈퍼패밀리의 단백질이다.

명명법

차별화 용어의 클러스터에서 APRIL은 CD256으로 지정됩니다.

기능.

이 유전자에 의해 코드된 단백질은 종양괴사인자배위자(TNF) 리간드 패밀리의 구성원이다.이 단백질은 TNF 수용체 패밀리의 구성원인 TNFRSF17/BCMA의 배위자이다.이 단백질과 그 수용체 모두 B세포 발달에 중요한 것으로 밝혀졌다.생체 내 실험은 골수에서 혈장 세포의 장기 생존에 있어 APRIL에 중요한 역할을 한다는 것을 시사한다.APRIL에 결핍된 쥐는 면역체계가 정상적으로 ^[7]발달한다.그러나 APRIL 결핍 쥐는 혈장 세포 ^[8]생존을 지원하는 능력이 저하된 것으로 보고되었다.시험관내 실험 결과, 이 단백질은 TNFRSF6/FAS 및 TNFRSF14/^[9]HVEM과 같은 다른 TNF 수용체 패밀리 단백질과의 상호작용을 통해 아포토시스를 유도할 수 있는 것으로 나타났다.별개의 등형질을 코드하는 이 유전자의 세 가지 대체적으로 스플라이스된 전사 변이가 보고되었다.

상호 작용

TNFSF13은 TNFRSF13B^[10] 및 B세포 활성화 ^[11]인자와 상호작용하는 것으로 나타났다.

임상적 의의

에이프릴은 자가면역질환과 B세포 악성종양의 ^[12]표적으로 연구되고 있다.적어도 하나의 항-APRIL 모노클로널 항체가 다발성 골수종에 ^[13]대한 I상 임상시험에 들어가는 것으로 발표되었다.

레퍼런스

^ ^a ^b ^c GRCh38: 앙상블 릴리즈 89: ENSG00000161955 - 앙상블, 2017년 5월
^ ^a ^b ^c GRCm38: 앙상블 릴리즈 89: ENSMUSG000089669 - 앙상블, 2017년 5월
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (September 1998). "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth". The Journal of Experimental Medicine. 188 (6): 1185–90. doi:10.1084/jem.188.6.1185. PMC 2212534. PMID 9743536.
^ "Entrez Gene: TNFSF13 tumor necrosis factor (ligand) superfamily, member 13".
^ Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Erickson S, French D, Schow P, Grewal IS, Ashkenazi A (February 2004). "APRIL-deficient mice have normal immune system development". Molecular and Cellular Biology. 24 (3): 997–1006. doi:10.1128/MCB.24.3.997-1006.2004. PMC 321448. PMID 14729948.
^ Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA (March 2008). "APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells". Blood. 111 (5): 2755–64. doi:10.1182/blood-2007-09-110858. PMID 18180376.
^ Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, Weller M (April 2001). "APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis". Cell Death and Differentiation. 8 (4): 403–10. doi:10.1038/sj.cdd.4400827. PMID 11550092.
^ Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D, LaFleur D, Migone TS, Nardelli B, Wei P, Ruben SM, Ullrich SJ, Olsen HS, Kanakaraj P, Moore PA, Baker KP (November 2000). "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS". The Journal of Biological Chemistry. 275 (45): 35478–85. doi:10.1074/jbc.M005224200. PMID 10956646.
^ Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS (October 2002). "BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases". Journal of Immunology. 169 (8): 4314–21. doi:10.4049/jimmunol.169.8.4314. PMID 12370363.
^ Ryan MC, Grewal IS (2009-01-01). Grewal IS (ed.). Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology. Vol. 647. New York: Springer. pp. 52–63. doi:10.1007/978-0-387-89520-8_4. ISBN 978-0-387-89519-2. PMID 19760066.
^ "Development of a first in class APRIL fully blocking antibody BION-1301 for the treatment of multiple myeloma". AACR 2017 Proceedings. April 2017.

추가 정보

Bossen C, Schneider P (October 2006). "BAFF, APRIL and their receptors: structure, function and signaling" (PDF). Seminars in Immunology. 18 (5): 263–75. doi:10.1016/j.smim.2006.04.006. PMID 16914324.
Tangye SG, Bryant VL, Cuss AK, Good KL (October 2006). "BAFF, APRIL and human B cell disorders". Seminars in Immunology. 18 (5): 305–17. doi:10.1016/j.smim.2006.04.004. PMID 16916610.
Treml LS, Crowley JE, Cancro MP (October 2006). "BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells". Seminars in Immunology. 18 (5): 297–304. doi:10.1016/j.smim.2006.07.001. PMID 16919470.
Mackay F, Leung H (October 2006). "The role of the BAFF/APRIL system on T cell function". Seminars in Immunology. 18 (5): 284–9. doi:10.1016/j.smim.2006.04.005. PMID 16931039.
Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
Shu HB, Hu WH, Johnson H (May 1999). "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens". Journal of Leukocyte Biology. 65 (5): 680–3. doi:10.1002/jlb.65.5.680. PMID 10331498. S2CID 1498303.
Cousin P, Billotte J, Chaubert P, Shaw P (January 2000). "Physical map of 17p13 and the genes adjacent to p53". Genomics. 63 (1): 60–8. doi:10.1006/geno.1999.6062. PMID 10662545.
Kelly K, Manos E, Jensen G, Nadauld L, Jones DA (February 2000). "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death". Cancer Research. 60 (4): 1021–7. PMID 10706119.
Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D, LaFleur D, Migone TS, Nardelli B, Wei P, Ruben SM, Ullrich SJ, Olsen HS, Kanakaraj P, Moore PA, Baker KP (November 2000). "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS". The Journal of Biological Chemistry. 275 (45): 35478–85. doi:10.1074/jbc.M005224200. PMID 10956646.
Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, McCabe S, Qiu WR, Kornuc M, Xia XZ, Guo J, Stolina M, Boyle WJ, Sarosi I, Hsu H, Senaldi G, Theill LE (September 2000). "APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity". Nature Immunology. 1 (3): 252–6. doi:10.1038/79802. PMID 10973284. S2CID 6799584.
López-Fraga M, Fernández R, Albar JP, Hahne M (October 2001). "Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase". EMBO Reports. 2 (10): 945–51. doi:10.1093/embo-reports/kve198. PMC 1084076. PMID 11571266.
Stein JV, López-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodríguez D, Gómez-Caro R, De Jong J, Martínez-A C, Medema JP, Hahne M (June 2002). "APRIL modulates B and T cell immunity". The Journal of Clinical Investigation. 109 (12): 1587–98. doi:10.1172/JCI15034. PMC 151011. PMID 12070306.
Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A (September 2002). "DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL". Nature Immunology. 3 (9): 822–9. doi:10.1038/ni829. PMC 4621779. PMID 12154359.
Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS (October 2002). "BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases". Journal of Immunology. 169 (8): 4314–21. doi:10.4049/jimmunol.169.8.4314. PMID 12370363.
Pradet-Balade B, Medema JP, López-Fraga M, Lozano JC, Kolfschoten GM, Picard A, Martínez-A C, Garcia-Sanz JA, Hahne M (November 2002). "An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein". The EMBO Journal. 21 (21): 5711–20. doi:10.1093/emboj/cdf565. PMC 131062. PMID 12411489.

외부 링크

TNFSF13+단백질+인간(미국 국립의학도서관 의학 과목 표제(MeSH))
UCSC Genome Browser의 인간 TNFSF13 게놈 위치 및 TNFSF13 유전자 세부 정보 페이지.

이 기사에는 미국 국립 의학 도서관(미국 국립 의학 도서관)의 공공 도메인 텍스트가 포함되어 있습니다.

[refGRCh38Ensembl-1] GRCh38: 앙상블 릴리즈 89: ENSG00000161955 - 앙상블, 2017년 5월

[refGRCm38Ensembl-2] GRCm38: 앙상블 릴리즈 89: ENSMUSG000089669 - 앙상블, 2017년 5월

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[pmid9743536-5] Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (September 1998). "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth". The Journal of Experimental Medicine. 188 (6): 1185–90. doi:10.1084/jem.188.6.1185. PMC 2212534. PMID 9743536.

[entrez-6] "Entrez Gene: TNFSF13 tumor necrosis factor (ligand) superfamily, member 13".

[7] Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Erickson S, French D, Schow P, Grewal IS, Ashkenazi A (February 2004). "APRIL-deficient mice have normal immune system development". Molecular and Cellular Biology. 24 (3): 997–1006. doi:10.1128/MCB.24.3.997-1006.2004. PMC 321448. PMID 14729948.

[entrez2-8] Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA (March 2008). "APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells". Blood. 111 (5): 2755–64. doi:10.1182/blood-2007-09-110858. PMID 18180376.

[9] Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, Weller M (April 2001). "APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis". Cell Death and Differentiation. 8 (4): 403–10. doi:10.1038/sj.cdd.4400827. PMID 11550092.

[pmid10956646-10] Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D, LaFleur D, Migone TS, Nardelli B, Wei P, Ruben SM, Ullrich SJ, Olsen HS, Kanakaraj P, Moore PA, Baker KP (November 2000). "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS". The Journal of Biological Chemistry. 275 (45): 35478–85. doi:10.1074/jbc.M005224200. PMID 10956646.

[pmid12370363-11] Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS (October 2002). "BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases". Journal of Immunology. 169 (8): 4314–21. doi:10.4049/jimmunol.169.8.4314. PMID 12370363.

[12] Ryan MC, Grewal IS (2009-01-01). Grewal IS (ed.). Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology. Vol. 647. New York: Springer. pp. 52–63. doi:10.1007/978-0-387-89520-8_4. ISBN 978-0-387-89519-2. PMID 19760066.

[13] "Development of a first in class APRIL fully blocking antibody BION-1301 for the treatment of multiple myeloma". AACR 2017 Proceedings. April 2017.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

v t 단백질: 분화의 클러스터(분화의 인간 클러스터 목록 참조)
1–50	CD1 교류 1A 1B 1차원 1E CD2 CD3 γ δ ε CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33 CD34 CD35 CD36 CD37 CD38 CD39 CD40 CD41 CD42 a b c d CD43 CD44 CD45 CD46 CD47 CD48 CD49 a b c d e f CD50
51–100	CD51 CD52 CD53 CD54 CD55 CD56 CD57 CD58 CD59 CD61 CD62 E L P CD63 CD64 A B C CD66 a b c d e f CD68 CD69 CD70 CD71 CD72 CD73 CD74 CD78 CD79 a b CD80 CD81 CD82 CD83 CD84 CD85 a d e h j k CD86 CD87 CD88 CD89 CD90 CD91 - CD92 CD93 CD94 CD95 CD96 CD97 CD98 CD99 CD100
101–150	CD101 CD102 CD103 CD104 CD105 CD106 CD107 a b CD108 CD109 CD110 CD111 CD112 CD113 CD114 CD115 CD116 CD117 CD118 CD119 CD120 a b CD121 a b CD122 CD123 CD124 CD125 CD126 CD127 CD129 CD130 CD131 CD132 CD133 CD134 CD135 CD136 CD137 CD138 CD140b CD141 CD142 CD143 CD144 CD146 CD147 CD148 CD150
151–200	CD151 CD152 CD153 CD154 CD155 CD156 a b c CD157 CD158 (a) d e i k) CD159 a c CD160 CD161 CD162 CD163 CD164 CD166 CD167 a b CD168 CD169 CD170 CD171 CD172 a b g CD174 CD177 CD178 CD179 a b CD180 CD181 CD182 CD183 CD184 CD185 CD186 CD191 CD192 CD193 CD194 CD195 CD196 CD197 CDW198 CDW199 CD200
201–250	CD201 CD202b CD204 CD205 CD206 CD207 CD208 CD209 CDW210 a b CD212 CD213a 1 2 CD217 CD218 (a) b) CD220 CD221 CD222 CD223 CD224 CD225 CD226 CD227 CD228 CD229 CD230 CD233 CD234 CD235 a b CD236 CD238 CD239 CD240CE CD240D CD241 CD243 CD244 CD246 CD247 - CD248 CD249
251–300	CD252 CD253 CD254 CD256 CD257 CD258 CD261 CD262 CD263 CD264 CD265 CD266 CD267 CD268 CD269 CD271 CD272 CD273 CD274 CD275 CD276 CD278 CD279 CD280 CD281 CD282 CD283 CD284 CD286 CD288 CD289 CD290 CD292 CDW293 CD294 CD295 CD297 CD298 CD299
301–350	CD300A CD301 CD302 CD303 CD304 CD305 CD306 CD307 CD309 CD312 CD314 CD315 CD316 CD317 CD318 CD320 CD321 CD322 CD324 CD325 CD326 CD327 CD328 CD329 CD331 CD332 CD333 CD334 CD335 CD336 CD337 CD338 CD339 CD340 CD344 CD349 CD350

Search